Blood mRNA expression of REV3L and TYMS as potential predictive biomarkers from platinum-based chemotherapy plus pemetrexed in non-small cell lung cancer patients.
María Teresa Agulló-OrtuñoInmaculada García-RuizC Vanesa Díaz-GarcíaAna B EnguitaVirginia Pardo-MarquésElena Prieto-GarcíaSantiago PonceLara IglesiasJon ZugazagoitiaJosé A López-MartínLuis Paz-AresJuan A NuñezPublished in: Cancer chemotherapy and pharmacology (2019)
The use of peripheral blood samples for expression quantification of interest genes is an affordable method with promising results in the evaluation of response to pemetrexed treatment. Therefore, expression levels of REV3L and TYMS genes might be used as predictive biomarkers in advanced NSCLC patients.
Keyphrases
- small cell lung cancer
- poor prognosis
- peripheral blood
- advanced non small cell lung cancer
- end stage renal disease
- genome wide
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- squamous cell carcinoma
- long non coding rna
- bioinformatics analysis
- genome wide identification
- cell therapy
- dna methylation
- epidermal growth factor receptor
- radiation therapy
- risk assessment
- locally advanced
- patient reported outcomes
- tyrosine kinase
- rectal cancer